Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN
Regeneron Pharmaceuticals — Corporate Update (January 2019)
13 slides from Regeneron Pharmaceuticals's corporate update, Jan 7, 2019
Slide 1: Note regarding Forward-Looking Statements and Non-GAAP Financial Measures
Note regarding FORWARD-LOOKING STATEMENTs and non-gaap financial measures 2 This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual ev
Slide 2: 2019 Financial Overview
2019 financial overview TAX OVERVIEW COGS & COCM LIBTAYO® ACCOUNTING REGENERON/SANOFI RESTRUCTURE IO COLLABORATION INTERACTIVE ANALYST CENTER 2018 tax review & 2019 and beyond guidance Review Cost of Goods Sold (COGS) & Cost of Collaboration and Contract Manufacturing (COCM) Review of accounting for
Slide 3: Tax Overview: 2018 Review
Tax overview: 2018 review 4 * as of November 6, 2018 Given the uncertainty due to the passage of the Tax Cuts and Jobs Act (TCJA) late in 2017 and the need for significant regulatory guidance from the U.S. Treasury, we have updated our effective tax rate guidance throughout 2018. The primary driver
Slide 4: Tax Overview: 2019 and Beyond
Tax Overview: 2019 and beyond 5 Tax Strategy and Longer-Term Rate Guidance 2019 Effective Tax Rate (ETR) Guidance 14 – 16% Positively impacted, as compared to 21% federal statutory rate, by: R&D and Orphan tax credits, foreign-derived intangible income (FDII) deduction, and deductions related to sha
Slide 5: LIBTAYO Accounting Review
LIBTAYO was approved in the U.S. on Sept 28, 2018 and approval is expected in the EU in 1H19 LIBTAYO® ACCOUNTING REVIEW 6 Aflibercept is an investigational medicine for the indications listed here. The safety and efficacy of this drug candidate has not been fully evaluated by any regulatory authorit
Slide 6: LIBTAYO Accounting Illustrative Example
Libtayo® accounting illustrative example 7 PLEASE NOTE ALL NUMBERS ARE ILLUSTRATIVE AND ARE NOT TO BE USED AS GUIDANCE Regeneron and Sanofi entered into a license agreement with Bristol-Myers Squibb Company, E. R. Squibb & Sons, L.L.C., and Ono Pharmaceutical Co., Ltd. and will pay royalties of 8.0%
Slide 7: Cost of Goods Sold (COGS) & Cost of Collaboration and Contract Manufacturing (COCM)
Cost of Goods sold (COGS) & Cost of Collaboration and Contract manufacturing (COCM) 8 Cost of Collaboration and Contract Manufacturing Cost of Goods Sold Costs related to products for which we record product sales (e.g., U.S. EYLEA®, ARCALYST®, U.S. LIBTAYO®): costs to manufacture commercial supplie
Slide 8: Regeneron/Sanofi Restructure IO Collaboration
REGENERON/SANOFI RESTRUCTURE IO COLLABORATION 9 Key Terms of Restructured Agreement Sanofi will pay Regeneron $462 million – its funding obligation for the remainder of the term of the agreement. This payment includes Sanofi’s share of 4Q18 costs, up to $120 million in dedicated development funding
Slide 9: Regeneron's Interactive Analyst Center
The Interactive Analyst Center is a repository of Regeneron’s historical reported financials and key operational data maintained by a third party This tool is meant to facilitate data gathering and to make researching Regeneron easier Access the Interactive Analyst Center via the Regeneron IR websit
Slide 10: 2019 Financial Guidance
11 2019 financial Guidance* * As of January 7, 2019. The guidance does not assume the completion of any significant business development transaction that had not been completed as of the date of the guidance. Regeneron does not undertake any obligation to update publicly any financial projection or
Slide 11: Reconciliation of Full Year 2019 Non-GAAP to GAAP Financial Guidance
12 Reconciliation of full year 2019 Non-GAAP to GAAP Financial guidance * Unreimbursed R&D represents R&D expenses reduced by R&D expense reimbursements from the Company's collaborators and/or customers Projected Range (in millions) Low High GAAP unreimbursed R&D* $ 1,855 $ 2,000 R&D: Non-cash share
Slide 12: Q&A
13 Aflibercept is an investigational medicine for the indications listed here. The safety and efficacy of this drug candidate has not been fully evaluated by any regulatory authority for the disease categories indicated here. Q&A
Slide 13: Q&A
Regeneron Pharmaceuticals — Corporate Update (January 2019) on 6ix